Essilor will unveil the pivotal two–year clinical trial results of its Stellest lens – its latest spectacle lens solution in the fight against myopia. The much–anticipated two–year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day.
Presentation in May
The presentation of this research entitled “Myopia control with spectacle lenses with aspherical lenslets: a 2–year randomized clinical trial”, will be delivered at the occasion of the Annual Meeting of the ARVO, on May 6th, 2021, by BAO Jinhua, Associate Professor at Wenzhou Medical University, China.
In 2018, Essilor’s research and development team initiated a three–year state–of–the–art clinical trial on 167 myopic children in its joint Research and Development Center shared with key partner, the Wenzhou Medical University, in China. This research illustrates Essilor’s commitment to fight poor vision and to find concrete solutions to slow down myopia progression in childhood.
According to Essilor, the results of this study demonstrate compelling evidence that Essilor Stellest lenses are one of the most effective options available for slowing down myopia progression in children today. Key outcomes include:
● After two years, children wearing Essilor Stellest lenses saved 0.99 diopters of myopia degree on average (67% slow–down in myopia progression on average), compared to single vision lenses, when worn 12 hours or more per dayeveryday.
● After the first year, the eye growth of 9 out of 10 children wearing Essilor Stellest lenses was similar or slower than non–myopic children.
● 2 out of 3 children who wore Essilor Stellest lenses did not need a prescription change after the first year
● 100% of children wearing Essilor Stellest lenses had clear vision, 100% of children adapted to their new lenses within a week; 91% of children fully adapted within three days; and 94% of children felt comfortable with Essilor Stellest lenses, demonstrating that Essilor Stellest lenses were comfortable, and easy to adapt for children.
Norbert Gorny, Co–Chief Operating Officer, Essilor International commented on the results, “With such impressive results, Essilor’s Stellest lenseswill truly be a catalyst to stem myopia progression and to help children, who continue to be at risk of sight–threatening eye conditions associated with myopia. Essilor is proud to be at the forefront of myopia management and we will continue to be focused on bringing such innovative advances to move the needle on the fight against myopia.”
Grita Loebsack, Group Chief Marketing Officer, Essilor International said,“These exciting results have already amazed leading global myopia experts and illustrate that Essilor’s mission and commitment to tackle myopia remains stronger than ever today. […] After its successful release in China in June 2020, then in Russia and Singapore, with extremely positive feedback from parents, children and eye care practitioners,we look forward to offering this new solution to help children in other countries.”
The Stellest lenses provide myopia correction through a single vision lens, which allows for sharp far vision and myopia control through H.A.L.T. technology, which consists of a constellation of aspherical lenslets spread on 11 rings and was designed to create for the first time, a volume of signal that slows down the elongation of the eye. The power of lenslets on each ring has been determined to guarantee a volume of signal always in front of the retina and following its shape, to achieve consistent myopia slowdown In addition to innovation and research, Essilor is committed to strengthening awareness and education of myopia with governments, healthcare and eye care professionals, and the wider public.